AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02468466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide prevention program as usual
Description: Usual mental health program (not including depression screening among middle-aged)
Study NCT01427205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
Study NCT01427205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: 150 mg by mouth twice a day.
Study NCT01427205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo taken by mouth twice daily.
Study NCT02953834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
Study NCT02953834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Resistance Test
Description: Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
Study NCT02953834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Resistance Test
Description: Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
Study NCT02953834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receive IV fluids for up to 16 hours that do not contain any study drug
Study NCT02561507 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Study NCT02554110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator active device
Description: This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
Study NCT02554110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stimulator sham Device
Description: This is an stimulator sham device that is not providing peripheral nerve stimulation.
Study NCT02592473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene Microspheres
Description: Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
Study NCT00128180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
Study NCT00128180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02028299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D doppler echo with Definity solution
Description: Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
Study NCT02093546 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tumor
Study NCT03417661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEXI-PREP By Clinell Wipes
Description: Sterile single sachet wipe containing 3ml solution.
Study NCT03417661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloraprep
Description: Sterile applicator containing 3ml solution.
Study NCT03417661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
Study NCT05796128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasal Intermittent Positive Pressure Ventilation (NIPPV)
Description: In this group, infants will receive NIPPV during LISA procedure.
Study NCT05796128 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Description: In this group, infants will receive NCPAP during LISA procedure.
Study NCT01173562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
Study NCT01854021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravenous anesthesia
Description: intravenous anesthesia
Study NCT01854021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined intravenous-inhalational anesthesia
Description: combined intravenous-inhalational anesthesia
Study NCT01854021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inhalational anesthesia
Description: inhalational anesthesia
Study NCT03363230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness skills training
Description: Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
Study NCT03363230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Effectiveness skills training
Description: Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
Study NCT02047110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by subcutaneous (SC) injection
Study NCT02047110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study NCT06067594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement
Description: Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
Study NCT01399359 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counseling session
Study NCT01399359 — intervention group
Intervention type: OTHER
Intervention: Questionnaire 1
Description: Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
Study NCT01399359 — intervention group
Intervention type: OTHER
Intervention: Questionnaire 2
Description: Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
Study NCT01399359 — intervention group
Intervention type: OTHER
Intervention: online questionnaire
Study NCT03152786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03152786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03152786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO
Study NCT03152786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03152786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03152786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03152786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03176953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prolonged exposure
Description: psychotherapy
Study NCT03176953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prolonged exposure
Description: psychotherapy
Study NCT01455116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild Induced Hypothermia
Description: Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
Study NCT03101709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
Study NCT03176953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: non-active medication
Study NCT03101709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
Study NCT03101709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
Study NCT03795922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109L will be injected into the GL.
Study NCT03795922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into the GL.
Study NCT01611571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: weekly risedronate
Study NCT01611571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: daily teriparatide
Study NCT02208934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: 5, 10, 20 and 40 mg of PBF-999
Study NCT02208934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for all dosis of PBF-999
Study NCT02198209 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liraglutide
Description: 1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c).
Study NCT02217397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OA, CPAP, combination therapy
Study NCT01615822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 100mg
Description: OZ439 100mg oral suspension, single dose
Study NCT01615822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 400mg
Description: OZ439 400mg oral suspension, single dose
Study NCT01611571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Teriparatide
Description: daily placebo of teriparatide
Study NCT01611571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo Risedronate
Description: weekly placebo of Risedronic Acid
Study NCT00548860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Study NCT00548860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Study NCT03413878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in the simulated avalanche snow
Description: Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
Study NCT00751088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension free vaginal ttape
Description: Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
Study NCT02672735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corrective Exercise Programming
Description: Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
Study NCT01061749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT01061749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01061749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01061749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study NCT04701775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Only Lactobacillus rhamnosus GG strains
Description: 1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule
Study NCT04701775 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains
Description: combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule
Study NCT04701775 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo probiotic capsule
Study NCT00458484 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions.
Study NCT00458484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Biopsy
Description: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
Study NCT00458484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum Blood Markers
Description: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
Study NCT01615822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MQ 250 mg, single dose
Description: Mefloquine 250 mg tablet, single dose
Study NCT01615822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MQ 750mg, single dose
Description: Mefloquine 750mg oral tablet, single dose
Study NCT03697811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Ophthalmic Solution
Description: Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
Study NCT01440946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
Study NCT01440946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIX
Description: Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
Study NCT04860310 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
Study NCT02577965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
Study NCT02577965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
Study NCT02577965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE PRIME Everolimus Eluting Coronary Stent System
Description: Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
Study NCT01615822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03759509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
Study NCT03813160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg
Description: oral capsule
Study NCT03813160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 5 mg
Description: oral capsule
Study NCT03813160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study NCT02577965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME Everolimus Eluting Coronary Stent System
Description: Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
Study NCT01652456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Addiction support
Description: one consultation with an addiction specialist
Study NCT02616003 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liraglutide
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
Study NCT02616003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aminosteril hepa 8%
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
Study NCT02616003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caloric diet with 1000 kcal
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
Study NCT02338752 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MV
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
Study NCT02338752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study NCT00289848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
Study NCT00289848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
Study NCT04066452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).
Description: Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
Study NCT01930058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8876
Description: MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
Study NCT03938142 — intervention group
Intervention type: OTHER
Intervention: Filling in an online survey regarding goalsettings
Description: Patients are asked to fill in an online survey regarding their individual goalsettings.
Study NCT01603875 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
Description: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention